Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flu pandemic mRNA vaccine
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Flu pandemic mRNA vaccine is an investigational messenger RNA (mRNA) vaccine candidate developed by GlaxoSmithKline. It is designed to induce an immune response against pandemic H5 influenza in healthy adults 18 to 85 years of age.
- Other names
- Flu Pandemic messenger RNA (mRNA) vaccinemRNA-based investigational pandemic H5 influenza vaccine candidate
02
Targets
H5 HA (Influenza A hemagglutinin H5)
Beyond the preview
Go deeper on flu pandemic mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flu pandemic mRNA vaccine.